Australian biotech market today 27/5/09
Wednesday, 27 May, 2009
The All Ordinaries are up nearly 1% to 3816.9 after a couple of days of fairly soft trading. The Health indicies are also up 1% in line with the ASX, although from a lower starting point following a slide that started Tuesday last week.
Ramsay Health Care (ASX:RHC) is up 23c to $11.08 following a 2009 financial year update suggesting core EPS growth will likely be 20%, buoyed by the low interest environment, and up from previous estimates of 10-12% growth.
ResMed, on the other hand, slipped 12c, or 2.5%, in the morning trading to $4.72 after another share buy-back, the third in a week.
Other trading was flat or in line with the overall market trend.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
